Distribution of rotavirus strains and strain-specific effectiveness of the rotavirus vaccine after its introduction: a systematic review and meta-analysis Dr Eyal Leshem, MD, Ben Lopman, PhD, Roger Glass, MD, Jon Gentsch, PhD, Krisztián Bányai, PhD, Umesh Parashar, MBBS, Manish Patel, MD The Lancet Infectious Diseases Volume 14, Issue 9, Pages 847-856 (September 2014) DOI: 10.1016/S1473-3099(14)70832-1 Copyright © 2014 Elsevier Ltd Terms and Conditions
Figure 1 Study selection *Ten studies reported both strain distribution and vaccine effectiveness. † Data were incomplete for G-type or P-type rotavirus strains only. ‡Included in the sensitivity analysis. The Lancet Infectious Diseases 2014 14, 847-856DOI: (10.1016/S1473-3099(14)70832-1) Copyright © 2014 Elsevier Ltd Terms and Conditions
Figure 2 Random-effect model of strain-specific rotavirus vaccine effectiveness, by country income level V=number vaccinated. N=total number of rotavirus cases or controls. RV1=monovalent rotavirus vaccine. RV5=pentavalent rotavirus vaccine. The Lancet Infectious Diseases 2014 14, 847-856DOI: (10.1016/S1473-3099(14)70832-1) Copyright © 2014 Elsevier Ltd Terms and Conditions
Figure 3 Rotavirus strain distribution after vaccine introduction Periods are 1 year from July to June (eg, July, 2006, to June, 2007). The Lancet Infectious Diseases 2014 14, 847-856DOI: (10.1016/S1473-3099(14)70832-1) Copyright © 2014 Elsevier Ltd Terms and Conditions
Figure 4 Country case studies of rotavirus strain distribution after vaccine introduction Periods are 1 year from July to June (eg, July, 2006, to June, 2007). RV1=monovalent rotavirus vaccine. RV5=pentavalent rotavirus vaccine. The Lancet Infectious Diseases 2014 14, 847-856DOI: (10.1016/S1473-3099(14)70832-1) Copyright © 2014 Elsevier Ltd Terms and Conditions